F2G Ltd (Manchester, UK) is a biopharmaceutical company focusing on the discovery and development of novel drugs for the treatment of life-threatening, systemic fungal diseases. 

The company has identified a novel pharmacological target that is specific to fungi, particularly the Aspergillus species. The company’s lead drug candidate is the first of a novel class of systemic anti-fungal agents and is currently in late-stage clinical development.


For more information, please contact:

Sten Verland, PhD MSc

General Partner

Phone +45 2422 1969